Systemic Lupus Erythematosus

Volume 1134 of the series Methods in Molecular Biology pp 67-78


Recombinant Antibody Microarray for Profiling the Serum Proteome of SLE

  • Carl A. K. BorrebaeckAffiliated withDepartment of Immunotechnology and CREATE Health, Lund University
  • , Gunnar SturfeltAffiliated withSection of Rheumatology, Department of Clinical Sciences, Skånes University Hospital, Lund University
  • , Christer WingrenAffiliated withDepartment of Immunotechnology and CREATE Health, Lund University

* Final gross prices may vary according to local VAT.

Get Access


Systemic lupus erythematosus (SLE) is a severe autoimmune connective tissue disease. Our current knowledge about the serum proteome, or serum biomarker panels, reflecting disease and disease status is still very limited. Affinity proteomics, represented by recombinant antibody arrays, is a novel, multiplex technology for high-throughput protein expression profiling of crude serum proteomes in a highly specific, sensitive, and miniaturized manner. The antibodies are deposited one by one in an ordered pattern, an array, onto a solid support. Next, the sample is added, and any specifically bound proteins are detected and quantified. The binding pattern is then converted into a relative protein expression map, or protein map, deciphering the composition of the sample at the molecular level. The methodology provides unique opportunities for delineating serum biomarkers reflecting SLE, thus paving the way for improved diagnosis, classification, and prognosis.


Antibody microarray Protein expression profiling SLE Biomarkers Diagnosis Prognosis Classification